<li>aceclofenac<p>aceclofenac increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>acemetacin<p>acemetacin increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>albiglutide<p>albiglutide, glyburide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Serious hypoglycemia may occur when insulin secretagogues and GLP-1 agonists are concurrently administered. Consider lowering the dose of insulin secretagogue to reduce the risk of hypoglycemia. .</p></li><li>alogliptin<p>alogliptin, glyburide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of alogliptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue .</p></li><li>aluminum hydroxide<p>aluminum hydroxide will increase the level or effect of glyburide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>aripiprazole<p>aripiprazole, glyburide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>asenapine<p>asenapine, glyburide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>aspirin<p>aspirin increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>aspirin rectal<p>aspirin rectal increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>atazanavir<p>atazanavir decreases effects of glyburide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>atorvastatin<p>glyburide increases toxicity of atorvastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>axitinib<p>glyburide increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>benazepril<p>benazepril increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects.</p></li><li>bexarotene<p>bexarotene increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor. Based on the mechanism of action, bexarotene capsules may increase the action of insulin enhancing agents, resulting in hypoglycemia. Hypoglycemia has not been associated with bexarotene monotherapy.</p></li><li>bezafibrate<p>bezafibrate increases effects of glyburide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>bitter melon<p>bitter melon increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>bosentan<p>bosentan decreases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inducers may increase glyburide metabolism.</p></li><li>calcium carbonate<p>calcium carbonate will increase the level or effect of glyburide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>canagliflozin<p>glyburide, canagliflozin.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.</p></li><li>capecitabine<p>capecitabine increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.</p></li><li>captopril<p>captopril increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood glucose. Monitor blood glucose.</p></li><li>carbamazepine<p>carbamazepine decreases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inducers may increase glyburide metabolism.</p></li><li>celecoxib<p>celecoxib increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>cholic acid<p>glyburide increases toxicity of cholic acid by decreasing elimination. Modify Therapy/Monitor Closely. Avoid concomitant use of inhibitors of the bile salt efflux pump (BSEP). May exacerbate accumulation of conjugated bile salts in the liver and result in clinical symptoms. If concomitant use is necessary, monitor serum transaminases and bilirubin.</p></li><li>choline magnesium trisalicylate<p>choline magnesium trisalicylate increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of glyburide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>cinnamon<p>cinnamon increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor. Potential for hypoglycemia.</p></li><li>ciprofibrate<p>ciprofibrate increases effects of glyburide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>ciprofloxacin<p>ciprofloxacin increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor. Hyper and hypoglycemia have been reported in patients treated concomitantly with quinolones and antidiabetic agents. Careful monitoring of blood glucose is recommended.</p></li><li>clarithromycin<p>clarithromycin increases levels of glyburide by plasma protein binding competition. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>clotrimazole<p>clotrimazole increases levels of glyburide by decreasing metabolism. Use Caution/Monitor.</p></li><li>clozapine<p>clozapine, glyburide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>colesevelam<p>colesevelam decreases levels of glyburide by drug binding in GI tract. Use Caution/Monitor. Concomitant administration decreases glyburide absorption; however, absorption is not reduced when glyburide is administered 4 hr before colesevelam.</p></li><li>daclatasvir<p>daclatasvir will increase the level or effect of glyburide by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>daclatasvir will increase the level or effect of glyburide by  Other (see comment). Use Caution/Monitor. Daclatasvir inhibits OATP1B1, OATP1B3, and BCRP. Caution if coadministered with drugs that are substrates of these transporters.</p></li><li>dapagliflozin<p>glyburide, dapagliflozin.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with dapagliflozin.</p></li><li>darunavir<p>darunavir decreases effects of glyburide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>delavirdine<p>delavirdine increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.</p></li><li>diclofenac<p>diclofenac increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>diflunisal<p>diflunisal increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>disopyramide<p>disopyramide increases effects of glyburide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>dulaglutide<p>dulaglutide, glyburide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>eliglustat<p>eliglustat increases levels of glyburide by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect.</p></li><li>eluxadoline<p>eluxadoline increases levels of glyburide by decreasing metabolism. Use Caution/Monitor. Eluxadoline may increase the systemic exposure of coadministered BCRP substrates.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df decreases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Elvitegravir is a moderate CYP2C9 inducer.</p></li><li>empagliflozin<p>empagliflozin, glyburide.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with SGLT2 inhibitors.</p></li><li>enalapril<p>enalapril increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>esomeprazole<p>esomeprazole will increase the level or effect of glyburide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>etodolac<p>etodolac increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>etoricoxib<p>etoricoxib increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>exenatide injectable solution<p>exenatide injectable solution, glyburide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypoglycemia when exenatide is used in combination with agents that induce hypoglycemia. Consider lowering dose of sulfonylureas to reduce risk of hypoglycemia. .</p></li><li>exenatide injectable suspension<p>exenatide injectable suspension, glyburide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypoglycemia when exenatide is used in combination with agents that induce hypoglycemia. Consider lowering dose of sulfonylureas to reduce risk of hypoglycemia.</p></li><li>famotidine<p>famotidine will increase the level or effect of glyburide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>fenbufen<p>fenbufen increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>fenofibrate<p>fenofibrate increases effects of glyburide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>fenofibrate micronized<p>fenofibrate micronized increases effects of glyburide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>fenofibric acid<p>fenofibric acid increases effects of glyburide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>fenoprofen<p>fenoprofen increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>fleroxacin<p>fleroxacin increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>flibanserin<p>glyburide will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.</p></li><li>fluconazole<p>fluconazole increases levels of glyburide by decreasing metabolism. Use Caution/Monitor.<span><br><br></span>fluconazole increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.</p></li><li>fluorouracil<p>fluorouracil increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.</p></li><li>fluoxetine<p>fluoxetine increases effects of glyburide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>flurbiprofen<p>flurbiprofen increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.<span><br><br></span>flurbiprofen increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.</p></li><li>fluvastatin<p>glyburide increases toxicity of fluvastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>fosamprenavir<p>fosamprenavir decreases effects of glyburide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>fosinopril<p>fosinopril increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>fosphenytoin<p>fosphenytoin decreases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inducers may increase glyburide metabolism.</p></li><li>gemfibrozil<p>gemfibrozil increases effects of glyburide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.<span><br><br></span>gemfibrozil increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.</p></li><li>gemifloxacin<p>gemifloxacin increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>ibuprofen<p>ibuprofen increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.<span><br><br></span>ibuprofen increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.</p></li><li>ibuprofen iv<p>ibuprofen iv increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.</p></li><li>iloperidone<p>iloperidone, glyburide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>imidapril<p>imidapril increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>indinavir<p>indinavir decreases effects of glyburide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>indomethacin<p>indomethacin increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.<span><br><br></span>indomethacin increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.</p></li><li>insulin aspart<p>glyburide, insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin aspart protamine/insulin aspart<p>glyburide, insulin aspart protamine/insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin degludec<p>glyburide, insulin degludec.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin degludec/insulin aspart<p>glyburide, insulin degludec/insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin detemir<p>glyburide, insulin detemir.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin glargine<p>glyburide, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin glulisine<p>glyburide, insulin glulisine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin inhaled<p>glyburide, insulin inhaled.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin isophane human/insulin regular human<p>glyburide, insulin isophane human/insulin regular human.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin lispro<p>glyburide, insulin lispro.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin lispro protamine/insulin lispro<p>glyburide, insulin lispro protamine/insulin lispro.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin nph<p>glyburide, insulin nph.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin regular human<p>glyburide, insulin regular human.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>isocarboxazid<p>isocarboxazid increases effects of glyburide by unknown mechanism. Use Caution/Monitor.</p></li><li>itraconazole<p>itraconazole increases levels of glyburide by decreasing metabolism. Use Caution/Monitor.</p></li><li>ivacaftor<p>glyburide increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors .</p></li><li>ketoconazole<p>ketoconazole increases levels of glyburide by decreasing metabolism. Use Caution/Monitor.<span><br><br></span>ketoconazole increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.</p></li><li>ketoprofen<p>ketoprofen increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>ketorolac<p>ketorolac increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>ketorolac intranasal<p>ketorolac intranasal increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>ketotifen, ophthalmic<p>ketotifen, ophthalmic, glyburide. Other (see comment). Use Caution/Monitor. 
Comment: Combination may result in thrombocytopenia (rare).  Monitor CBC.</p></li><li>levofloxacin<p>levofloxacin increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>linagliptin<p>glyburide, linagliptin. Other (see comment). Use Caution/Monitor. 
Comment: When linagliptin is used in combination with sulfonylureas, a lower dose of the sulfonylurea may be required to reduce risk of hypoglycemia.</p></li><li>linezolid<p>linezolid increases effects of glyburide by unknown mechanism. Use Caution/Monitor.</p></li><li>liraglutide<p>liraglutide, glyburide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Serious hypoglycemia may occur when insulin secretagogues and GLP-1 agonists are concurrently administered. Consider lowering the dose of insulin secretagogue to reduce the risk of hypoglycemia. .</p></li><li>lisinopril<p>lisinopril increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>lixisenatide<p>lixisenatide, glyburide.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Risk of hypoglycemia increased when coadministered with sulfonylureas. Sulfonylurea dosage reduction may be required.</p></li><li>lomitapide<p>glyburide increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.</p></li><li>lopinavir<p>lopinavir decreases effects of glyburide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>lornoxicam<p>lornoxicam increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>lurasidone<p>lurasidone, glyburide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>marijuana<p>marijuana decreases effects of glyburide by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>mecasermin<p>mecasermin increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects.</p></li><li>meclofenamate<p>meclofenamate increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>mefenamic acid<p>mefenamic acid increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.<span><br><br></span>mefenamic acid increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.</p></li><li>meloxicam<p>meloxicam increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>metreleptin<p>glyburide, metreleptin.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue.</p></li><li>miconazole vaginal<p>miconazole vaginal increases levels of glyburide by decreasing metabolism. Use Caution/Monitor.</p></li><li>mipomersen<p>mipomersen, glyburide.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.</p></li><li>moexipril<p>moexipril increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>moxifloxacin<p>moxifloxacin increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>nabumetone<p>nabumetone increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>nadolol<p>nadolol decreases effects of glyburide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.</p></li><li>naproxen<p>naproxen increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>nelfinavir<p>nelfinavir decreases effects of glyburide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>nicardipine<p>nicardipine increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.</p></li><li>nitazoxanide<p>nitazoxanide, glyburide.
Either increases levels of the other by Mechanism: plasma protein binding competition. Use Caution/Monitor.</p></li><li>nitisinone<p>nitisinone will increase the level or effect of glyburide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index.</p></li><li>norfloxacin<p>norfloxacin increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>ofloxacin<p>ofloxacin increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>olanzapine<p>olanzapine, glyburide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of glyburide by  Other (see comment). Use Caution/Monitor. Paritaprevir inhibits OATP1B1, OATP1B3, and BCRP. Ritonavir inhibits BCRP. Caution if coadministered with drugs that are substrates of these transporters.<span><br><br></span>ombitasvir/paritaprevir/ritonavir will increase the level or effect of glyburide by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Paritaprevir and ritonavir inhibit P-gp. Caution if coadministered with P-gp substrates.</p></li><li>omeprazole<p>omeprazole will increase the level or effect of glyburide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>opuntia ficus indica<p>opuntia ficus indica increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>osimertinib<p>osimertinib will increase the level or effect of glyburide by  Other (see comment). Modify Therapy/Monitor Closely. Osimertinib is an inhibitor of BCRP transport. Caution if coadministered with sensitive BCRP substrates.</p></li><li>ospemifene<p>glyburide, ospemifene.
Either increases levels of the other by plasma protein binding competition. Modify Therapy/Monitor Closely.</p></li><li>oxaprozin<p>oxaprozin increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>paliperidone<p>paliperidone, glyburide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>parecoxib<p>parecoxib increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>peginterferon alfa 2b<p>peginterferon alfa 2b decreases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. .</p></li><li>perindopril<p>perindopril increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>phenelzine<p>phenelzine increases effects of glyburide by unknown mechanism. Use Caution/Monitor.</p></li><li>phenobarbital<p>phenobarbital decreases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inducers may increase glyburide metabolism.</p></li><li>phenytoin<p>phenytoin decreases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inducers may increase glyburide metabolism.</p></li><li>pindolol<p>pindolol decreases effects of glyburide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.</p></li><li>piroxicam<p>piroxicam increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.<span><br><br></span>piroxicam increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.</p></li><li>pitavastatin<p>glyburide increases toxicity of pitavastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>ponatinib<p>ponatinib increases levels of glyburide by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>ponatinib increases levels of glyburide by Other (see comment). Use Caution/Monitor.</p></li><li>posaconazole<p>posaconazole increases levels of glyburide by decreasing metabolism. Use Caution/Monitor.</p></li><li>pravastatin<p>glyburide increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>primidone<p>primidone decreases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inducers may increase glyburide metabolism.</p></li><li>probenecid<p>probenecid increases levels of glyburide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>propranolol<p>propranolol decreases effects of glyburide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.</p></li><li>quetiapine<p>quetiapine, glyburide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>quinapril<p>quinapril increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>ramipril<p>ramipril increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>ranitidine<p>ranitidine will increase the level or effect of glyburide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>regorafenib<p>regorafenib will increase the level or effect of glyburide by  Other (see comment). Modify Therapy/Monitor Closely. Regorafenib likely inhibits BCRP (ABCG2) transport. Coadministration with a BCRP substrate may increase systemic exposure to the substrate and related toxicity.</p></li><li>rifabutin<p>rifabutin decreases levels of glyburide by increasing metabolism. Use Caution/Monitor.</p></li><li>rifampin<p>rifampin decreases levels of glyburide by increasing metabolism. Use Caution/Monitor.<span><br><br></span>rifampin decreases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inducers may increase glyburide metabolism.</p></li><li>rifapentine<p>rifapentine decreases levels of glyburide by increasing metabolism. Use Caution/Monitor.<span><br><br></span>rifapentine decreases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inducers may increase glyburide metabolism.</p></li><li>risperidone<p>risperidone, glyburide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>ritonavir<p>ritonavir, glyburide. Other (see comment). Use Caution/Monitor. 
Comment: Ritonavir may increase or decrease levels of glyburide. Use alternatives if available. Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>rosuvastatin<p>glyburide increases toxicity of rosuvastatin by Other (see comment). Use Caution/Monitor. 
Comment: Coadministration of rosuvastatin with OATP1B1 inhibitors may increase rosuvastatin levels and risk for myopathy.</p></li><li>sacubitril/valsartan<p>glyburide will increase the level or effect of sacubitril/valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>salicylates (non-asa)<p>salicylates (non-asa) increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>salsalate<p>salsalate increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>saquinavir<p>saquinavir decreases effects of glyburide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>secobarbital<p>secobarbital decreases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inducers may increase glyburide metabolism.</p></li><li>selegiline<p>selegiline increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Serum glucose should be monitored closely when MAOIs are added to any regimen containing antidiabetic medications. Hypoglycemic effects may be increased.</p></li><li>selegiline transdermal<p>selegiline transdermal increases effects of glyburide by unknown mechanism. Use Caution/Monitor.</p></li><li>shark cartilage<p>shark cartilage increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor. Theoretical interaction.</p></li><li>simvastatin<p>glyburide increases toxicity of simvastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>sodium bicarbonate<p>sodium bicarbonate will increase the level or effect of glyburide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>sodium citrate/citric acid<p>sodium citrate/citric acid will increase the level or effect of glyburide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>sofosbuvir/velpatasvir<p>sofosbuvir/velpatasvir will increase the level or effect of glyburide by  Other (see comment). Use Caution/Monitor. Velpatasvir is an inhibitor of the drug transporter BCRP. Coadministration may increase systemic exposure of drugs that are BCRP substrates.</p></li><li>sulfadiazine<p>sulfadiazine increases levels of glyburide by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>sulfadiazine increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.</p></li><li>sulfamethoxazole<p>sulfamethoxazole increases levels of glyburide by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.</p></li><li>sulfamethoxypyridazine<p>sulfamethoxypyridazine increases effects of glyburide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>sulfasalazine<p>sulfasalazine increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>sulfisoxazole<p>sulfisoxazole increases levels of glyburide by plasma protein binding competition. Use Caution/Monitor.</p></li><li>sulindac<p>sulindac increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>timolol<p>timolol decreases effects of glyburide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.</p></li><li>tipranavir<p>tipranavir decreases effects of glyburide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>tolbutamide<p>tolbutamide increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.</p></li><li>tolfenamic acid<p>tolfenamic acid increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>tolmetin<p>tolmetin increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>trandolapril<p>trandolapril increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>tranylcypromine<p>tranylcypromine increases effects of glyburide by unknown mechanism. Use Caution/Monitor.</p></li><li>trimagnesium citrate anhydrous<p>trimagnesium citrate anhydrous increases levels of glyburide by enhancing GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>valsartan<p>glyburide will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>voriconazole<p>voriconazole increases levels of glyburide by decreasing metabolism. Use Caution/Monitor.<span><br><br></span>voriconazole increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.</p></li><li>xipamide<p>xipamide decreases levels of glyburide by increasing renal clearance. Use Caution/Monitor.</p></li><li>ziprasidone<p>ziprasidone, glyburide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li>